A patient with severe sickle cell disease (SCD) remained free of two key SCD symptoms — including painful…
Articles by Steve Bryson, PhD
Higher blood levels of erythropoietin (EPO), a hormone that stimulates the production of red blood cells, increase the risk of…
The use of pharmaceutical disease-modifying therapies (pDMTs) has increased in recent years among both children and adults with sickle…
Agios Pharmaceuticals has filed an application with the U.S. Food and Drug Administration (FDA) seeking accelerated approval of mitapivat,…
Sickle cell disease (SCD) hospitalization patterns vary across New York State, with New York City showing the largest share…
Beam Therapeutics plans to ask the U.S. Food and Drug Administration (FDA) to approve ristoglogene autogetemcel, or risto-cel, its…
A high dose of pociredir, Fulcrum Therapeutics’ oral drug candidate for sickle cell disease (SCD), boosted fetal hemoglobin…
In a mouse study, blood stem cells from sickle cell disease (SCD) patients modified with CRISPR/Cas9 gene editing showed…
Risto-cel, Beam Therapeutics‘ single-dose, gene-edited cell therapy candidate for people with severe sickle cell disease (SCD), continues to…
Vascarta‘s VAS‑101, a skin gel containing curcumin — a component of the spice turmeric — was found in laboratory…